• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Case report: Diagnosis clouded by concomitant glaucoma and giant cell arteritis

Optometry Times JournalVol. 11 No. 1
Volume 11
Issue 1

Figure 1. RNFL differs significantly between OD and OS.

A 65-year-old Caucasian male presented as a work-in appointment with a chief complaint of sudden painless vision loss in the right eye, gradually worsening over the prior week.

When asked, he admitted to a right-sided temporal headache. He denied having jaw claudication, neck pain, or scalp tenderness, and his temporal artery was not particularly palpable or different from his left side.

His medical history was pertinent for Type 2 diabetes mellitus (with unknown A1C or blood sugar), hypertension, and high cholesterol, with compliance to all medications.

He admitted to not having had an eye exam in over a decade and reported no family history of ocular disease.

Related: Applying precision medication to glaucoma and genomics

Clinical findings
Best-corrected visual acuities were counting fingers at 4 feet in the right eye and 20/30 in the left eye. Confrontation visual fields showed an inferior temporal

defect in the right eye with a full field in the left eye.

While facial symmetry and extraocular motility were normal without proptosis or ptosis, a 2+ afferent pupillary defect was found in the right eye.

His anterior segment exam was unremarkable.

Intraocular pressure (IOP) by Goldmann applanation tonometry was 31 mm Hg in both eyes. Upon finding elevated IOP, gonioscopy was performed, and a Grade 4 open angle was noted in all four quadrants in both eyes.

Dilated fundus exam of the right eye revealed a pale optic nerve with subtly indistinct margins but no perceptible elevation and a 0.4 cup-to-disc ratio. The optic nerve in the left eye had distinct margins and a 0.5 cup-to-disc ratio.

Pachymetry readings were 571 µm OD and 578 µm OS.

Related: Why documenting target IOP helps ODs

Blood pressure was 171/97 mm HG, which was reported by the patient to be “normal” for him.

Optic nerve OCT was performed (see Figure 1).

Figure 2. OCT after steroid therapy reveals severely thin RNFL OD with optic nerve cupping (note artifact in the right eye).

Even with a non-thin retinal nerve fiber layer (RNFL) in the right eye, the high bilateral IOPs deemed it necessary to follow the community standard of care by initiating an in-office topical IOP treatment in both eyes.

After one drop of Alphagan P (brimonidine 0.1%, Allergan), IOP reached 22 mm Hg OD and 25 mm Hg OS before the patient left the office. He was given a sample of Simbrinza (brinzolamide 1%/brimonidine 0.2%, Novartis) to use three times daily in both eyes.

The patient was sent for same-day bloodwork with his primary-care physician (PCP) for complete blood count (CBC) with differential, erythrocyte sedimentation rate (ESR or sed rate), and C-reactive protein (CRP). A strong recommendation was given to the patient to manage his hypertension, and a prompt letter was sent to the PCP accordingly.

In addition to being a glaucoma suspect, differential diagnoses included both arteritic and non-arteritic anterior ischemic optic neuropathy, optic neuritis, and compressive lesion. Judging by this patient’s age, temporal headache, and the sudden and profound nature of his vision loss, arteritic anterior ischemic optic neuropathy (AAION) was highly suspected.

At his next day follow-up visit, visual field 24-2 was performed, which revealed a severe central visual field defect in the right eye and superior arcuate defect with nasal step in the left, corresponding to his OCT.

ESR and CRP were both significantly elevated: 46 and 6.9, respectively.

The patient was sent the same day to rheumatology for giant cell arteritis evaluation and was started on 40 mg of oral prednisone.

Temporal artery biopsy came back inconclusive, but after six weeks of oral steroids, the patient’s vision had improved to 20/100 OD, and his IOPs were much improved.

Related: OCT helps diagnose retinoschisis in glaucoma patients

An optic nerve OCT was repeated (see Figure  2). The optic nerve swelling had resolved and subsequently revealed what was likely a combination of both post-AAION cupping and glaucomatous cupping.

Because both glaucoma and post-AAION status derive from similar vascular mechanisms, it is suggested that the acute ischemic event in an AAION acts as a faster version of the chronic ischemia occurring in glaucomatous optic neuropathy.1

Consequently, this patient is now being tapered off of oral prednisone and is being managed for glaucoma.

Concerning this patient, there are two distinct diagnoses: primary open-angle glaucoma and AAION caused by giant cell arteritis. Glaucoma was confirmed by low RNFL, elevated IOP, and corresponding visual field loss. AAION was confirmed by history, symptoms, elevated ESR/CRP, and RNFL elevation.

This case was complicated by the fact that there was no obvious optic nerve elevation seen on slit-lamp biomicroscopy, thus OCT had to be utilized to confirm disc edema.

Per the baseline OCT, it appears that the right eye has somewhat “normal” RNFL. These results are likely explained by assuming that the right eye started out with a lower RNFL thickness secondary to the undiagnosed glaucoma; however, with the mild disc edema, the retinal nerve fiber layer became artificially “normal.”

Related: Knowing when to delegate testing responsibilities 

A small study showed that IOP is usually significantly lower in patients with giant cell arteritis, with hypotony occurring in one third of these cases.2 The difference in this case resulted from the concomitant glaucoma, causing IOPs to be high.

Additionally, in patients with giant cell arteritis, it is not likely that vision will improve after initiation of corticosteroid therapy, but this patient was part of the approximately 34 percent of patients who do have small improvement after steroid treatment.3

In a case such as this, communication with other specialties is vital. If AAION is suspected, time is crucial, and same-day bloodwork and urgent rheumatology consultation are both imperative. 

This case additionally highlights the importance of noting the presence of concomitant illnesses. Currently there is no known causative relationship between AAION and glaucoma, but their similarities lie in vascular origin.1 In the future, optical coherence tomography angiography (OCT-A) may prove to be an important tool in the management of cases like this with ischemic optic nerve conditions.4  

Read more about glaucoma 


1. Hayreh SS, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology. 2001 Sep;108(9):1586-94.
2. Huna-Baron R, Mizrachi IB, Glovinsky Y. Intraocular pressure is low in eyes with giant cell arteritis. J Neuro-Ophthalmol. 2006 Dec;26(4):273-5.
3. Liu GT, Glaser, JS, Schatz, NJ, Smith, JL. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis of vision. Ophthalmology. 1994 Nov;101(11):1779-85. 101.
4. Balducci N, Morara M, Veronese C, Barboni P, Casadei NL, Savini G, Parisi V, Sadun AA, Ciardella A. Optical coherence tomography angiography in acute arteritic and non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2255-2261.

Related Videos
Lorraine Provencher, MD, presenting slides
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Melissa Tawa, OD, FAAO
Deborah Ristvedt, DO, details CIME 2024 presentation on glaucoma management
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
© 2024 MJH Life Sciences

All rights reserved.